IDIOPATHIC PULMONARY FIBROSIS
Clinical trials for IDIOPATHIC PULMONARY FIBROSIS explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC PULMONARY FIBROSIS trials appear
Sign up with your email to follow new studies for IDIOPATHIC PULMONARY FIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for lung scarring? trial of GSK3915393 cut short
Disease control TerminatedThis study tested a new medicine, GSK3915393, in 158 people with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and breathing difficulty. The goal was to see if the drug could slow lung function decline compared to a placebo. The trial was termin…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental drug vixarelimab tested for two scarring lung diseases
Disease control TerminatedThis study tested the drug vixarelimab against a placebo in people with idiopathic pulmonary fibrosis (IPF) or systemic sclerosis-associated interstitial lung disease (SSc-ILD). The goal was to see if it could preserve lung function over 52 weeks. The trial was terminated early, …
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Lung fibrosis drug study halted early
Disease control TerminatedThis study tested new single treatments for idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and makes breathing hard. It included 46 adults aged 40 and older with mild to moderate IPF. The main goal was to see if the treatments improved lung function, mea…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Promising IPF drug trial halted midway
Disease control TerminatedThis study tested an experimental drug called HZN-825 in people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and makes breathing hard. The trial aimed to see if the drug could slow the decline in lung function over a year. About 153 adults with IP…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill aims to quiet debilitating cough in lung scarring disease
Symptom relief TerminatedThis study tested an experimental drug called BI 1839100 in adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF) who have a chronic cough. Participants took different doses of the drug or a placebo for 12 weeks. The goal was to see if the drug c…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
New lung camera could replace needle biopsies
Knowledge-focused TerminatedThis study aimed to see if a tiny camera on a thin tube (bronchoscopy) could help doctors diagnose diffuse lung diseases without needing a surgical lung biopsy. The camera takes live microscopic images of the air sacs. The study was stopped early, but it involved 38 adults with c…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Sleep apnea machine tested for IPF lung health – but study stopped early
Knowledge-focused TerminatedThis study looked at whether using a CPAP machine at night could reduce abnormal acid reflux and lung inflammation in people with idiopathic pulmonary fibrosis (IPF) who also have sleep apnea. Only 7 people enrolled before the study was terminated early. The goal was to measure c…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: NA • Sponsor: University of Arizona • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC